Front. Immunol. Frontiers in Immunology Front. Immunol. 1664-3224 Frontiers Media S.A. 10.3389/fimmu.2022.1104646 Immunology Correction Corrigendum: rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis Shen Weiran 1 Liu Shengjiang 2 Ou Li 3 4 * 1 Obio Technologies, Shanghai, China 2 Avirmax Inc, Hayward, CA, United States 3 Genemagic Biosciences, Wallingford, PA, United States 4 Department of Pediatrics, University of Minnesota, Minneapolis, MN, United States

Edited and reviewed by: Arun Srivastava, University of Florida, United States

*Correspondence: Li Ou, ouxxx045@umn.edu

This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology

 18 01 2023 2022 13 1104646 21 11 2022 29 11 2022 Copyright © 2023 Shen, Liu and Ou 2023 Shen, Liu and Ou

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis by Shen W, Liu S and Ou L (2022) Front. Immunol. 13:1001263. doi: 10.3389/fimmu.2022.1001263 rAAV clinical trials immunogenicity toxicity neutralizing antibodies immunosuppressants capsids gene therapy

In the published article, there was an error in Table 2 as published. Row 1, column 6 of the table should be “undisclosed” instead of “rBac-Sf9”. Furthermore, the row “Inflammatory arthritis” was removed as the death that occurred in that clinical trial was not AAV-related. The corrected Table 2 and its caption “Table 2. Patient deaths that occurred in AAV-related clinical trials” appear below.

Patient deaths that occurred in AAV-related clinical trials.

Disease Trial ID Drug name Serotype ROA Production Patient deaths References
DMD NCT03362502 PF-06939926 AAV9 Intravenous Undisclosed 1 37
ALS N/A AAV-miR-SOD1 AAVrh10 Intrathecal HEK293 1 38
MPS IIIA NCT03612869 SAF-302 AAVrh10 Intracerebral HEK293 1 39
GAN NCT02362438 TSHA-120 AAV9 Intrathecal HEK293 1 40
GM2 gangliosidosis NCT04798235 TSHA-101 AAV9 Intrathecal HEK293 1 41
SMA NCT03461289 Zolgensma AAV9 Intravenous HEK293 1* 42
XLMTM NCT03199469 AT132 AAV8 Intravenous HEK293 4 43, 44

Two patient deaths were recently reported when Zolgensma is commercially used, and no detailed information was released yet (45). One patient death in a clinical trial for arthritis was excluded because it was deemed not be related with AAV (46). ALS, amyotrophic lateral sclerosis; GAN, giant axonal neuropathy; SMA, spinal muscular atrophy.

In the published article, there was an error in the legend for Table 2 as published. We have removed one row in Table 2 , so the Table legend needs to be updated accordingly. The corrected legend appears below.

“Two patient deaths were recently reported when Zolgensma is commercially used, and no detailed information was released yet (45). One patient death in a clinical trial for arthritis was excluded because it was deemed not be related with AAV (46). ALS, amyotrophic lateral sclerosis; GAN, giant axonal neuropathy; SMA, spinal muscular atrophy.”

In the published article, there was an error in Figure 6 as published. In Figure 6B , both column “patient deaths” and “deaths per trial” for rBac-Sf9 should be 0. The corrected Figure 6 and its caption “Figure 6. Manufacturing systems of 255 AAV clinical trials” appear below.

Manufacturing systems of 255 AAV clinical trials. (A) System usage in different time periods. (B) Patient deaths in trials using different manufacturing systems. Trials that did not report manufacturing systems are not included for analysis.

In the published article, there was an error. There was no patient death for the rBac/Sf9 system. Our information source on one trial was wrong.

A correction has been made to Results, Production system. This sentence previously stated:

“Also, a total of 9 patient deaths occurred in 134 AAV trials using the HEK293 system, while there is one individual death for both rBac/Sf9 system (n=36) and producer cell line system (n=24) ( Figure 6B ).”

The corrected sentence appears below:

“Also, a total of 9 patient deaths occurred in 134 AAV trials using the HEK293 system, while there is one individual death for the producer cell line system (n=24) ( Figure 6B ).”

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.